Loading…
NextCure, Inc. is projected to decline to $1.94 by 2027, a -3% move from its current price of $2.00. NXTC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.86 | $2.00 | $2.15 | -0.03% |
| Jul 13 | $1.80 | $2.00 | $2.22 | -0.06% |
| Jul 14 | $1.76 | $2.00 | $2.27 | -0.09% |
| Jul 15 | $1.72 | $2.00 | $2.32 | -0.12% |
| Jul 16 | $1.69 | $2.00 | $2.36 | -0.15% |
| Jul 17 | $1.66 | $2.00 | $2.40 | -0.18% |
| Jul 18 | $1.64 | $2.00 | $2.43 | -0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.64 | $2.00 | $2.43 | -0.21% |
| Week 2 | $1.51 | $1.99 | $2.63 | -0.42% |
| Week 3 | $1.41 | $1.99 | $2.80 | -0.64% |
| Week 4 | $1.34 | $1.98 | $2.94 | -0.85% |
| Week 5 | $1.27 | $1.98 | $3.08 | -1.06% |
| Week 6 | $1.22 | $1.97 | $3.21 | -1.27% |
| Week 7 | $1.17 | $1.97 | $3.32 | -1.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on advancing medicines to treat cancer. Its product candidate is LNCB74, a B7-H4 targeted ADC to kill tumors, and it also develops NC410, a fusion protein of LAIR-2 designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181, a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605, an antibody that targets Siglec-15, as well as SIM0505, a novel antibody-drug conjugate targeting CDH6 for the treatment of solid tumors.
The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC is NextCure, Inc., a biotechnology company engaged in oncology and immunology research with a cancer-focused portfolio. The stock trades at a current price of $2.00 and carries a market capitalization of $7.22M, with a market rank of 5231. The long-term price outlook shows a wide forecast range, including a peak forecast of $14.16 and a multi-year path that reaches higher levels by 2050, though near-term results are mixed across years.
A major floor 20.0% below — a decisive break under it would weaken the trend.
The nearest floor, 20.0% below — buyers have tended to step in here.
The nearest ceiling, 220.0% above — a clean break opens room to run.
A major ceiling 580.0% above — clearing it would confirm fresh momentum.
Key NXTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NXTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.92 | Buy | $1.92 | Buy |
| MA 10 | $1.84 | Buy | $1.92 | Buy |
| MA 20 | $1.89 | Buy | $2.36 | Sell |
| MA 50 | $5.18 | Sell | $4.61 | Sell |
| MA 100 | $8.45 | Sell | $6.85 | Sell |
| MA 200 | $9.57 | Sell | $8.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.29 | Neutral |
| Stoch RSI (14) | 97.57 | Sell |
| CCI (20) | 33.55 | Neutral |
| Williams %R (14) | -21.28 | Info |
| MACD (12,26,9) | 0.28 | Buy |
| ROC (12) | 8.84 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 78.72 | Neutral |
| TRIX (15) | -4.14 | Sell |
| Awesome (5,34) | -1.17 | Sell |
| Ultimate (7,14,28) | 54.29 | Neutral |
| Momentum (10) | 0.32 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 1.92 | Buy |
| ADX (14) | 44.07 | Sell |
| ATR (14) | 0.22 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 30, indicating modest tilts toward oversold conditions without a clear bullish trend. The stock’s 50-day simple moving average is $5.32 and the 200-day simple moving average is $9.59, highlighting a gap between the current price and longer-term averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.60 | $2.00 | $2.84 | 0% | Neutral | |
| $1.40 | $1.94 | $2.88 | -3% | Neutral | |
| $1.23 | $1.81 | $2.87 | -10% | Neutral | |
| $0.9405 | $1.45 | $2.42 | -27% | Bearish | |
| $1.05 | $1.69 | $2.93 | -15% | Bearish | |
| $1.39 | $2.35 | $4.22 | +17% | Neutral | |
| $1.26 | $2.23 | $4.13 | +12% | Neutral | |
| $1.31 | $2.41 | $4.59 | +20% | Bullish | |
| $1.23 | $2.34 | $4.57 | +17% | Neutral | |
| $0.9224 | $1.83 | $3.66 | -8% | Neutral | |
| $1.22 | $2.70 | $5.93 | +35% | Bullish | |
| $2.76 | $6.14 | $14.13 | +207% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.60 | $2.00 | $2.42 | +0.00% |
| August 2026 | $1.55 | $1.88 | $2.37 | -6.18% |
| September 2026 | $1.58 | $1.95 | $2.51 | +3.68% |
| October 2026 | $1.69 | $2.11 | $2.76 | +8.35% |
| November 2026 | $1.68 | $2.11 | $2.81 | +0.33% |
| December 2026 | $1.66 | $2.10 | $2.84 | -0.49% |
Click any year to see its month-by-month NXTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NextCure, Inc.'s 2026 outlook centres on $2.00, within a $1.60 to $2.84 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NXTC could reach as high as $2.88, with a base case around $1.94 and support toward $1.40 — roughly -3% from $2.00. A consolidation phase looks the most probable path here.
Expect NXTC to range from $1.23 to $2.87 through 2028. The $1.81 average target implies a -10% move from current prices. That is -7% versus the projected 2027 average. Price action looks broadly range-bound.
The NXTC price prediction for 2029 points to an average of $1.45 (low $0.9405, high $2.42) — a potential decline of -27% on today's $2.00. Expect choppier, lower action through this leg of the cycle.
In 2030, NXTC is projected to trade between $1.05 and $2.93, averaging $1.69 — a potential decline of -15% from today's $2.00. That is up +16% on the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
NextCure, Inc.'s 2031 outlook centres on $2.35, within a $1.39 to $4.22 range. That is up +39% on the projected 2030 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, NXTC could reach as high as $4.13, with a base case around $2.23 and support toward $1.26 — roughly +12% from $2.00. Price action looks broadly range-bound.
Expect NXTC to range from $1.31 to $4.59 through 2033. The $2.41 average target implies a +20% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NXTC price prediction for 2034 points to an average of $2.34 (low $1.23, high $4.57) — a potential gain of +17% on today's $2.00. Price action looks broadly range-bound.
In 2035, NXTC is projected to trade between $0.9224 and $3.66, averaging $1.83 — a potential decline of -8% from today's $2.00. That is -22% versus the projected 2034 average. A consolidation phase looks the most probable path here.
NextCure, Inc.'s 2040 outlook centres on $2.70, within a $1.22 to $5.93 range. That is up +48% on the projected 2035 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2050, NXTC could reach as high as $14.13, with a base case around $6.14 and support toward $2.76 — roughly +207% from $2.00. Buyers look set to stay in control over this stretch.
Investing $1,000 in NXTC today (≈ 500 NXTC) could be worth
$3,071.48
+$2,071.48 (+207%) by 2050 · US Dollar
Based on the average projected NXTC price of $6.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NXTCwould be worth at today's price.
$1,000 invested in NXTC on Jul 10, 2025 (≈ 178.062672 NXTC) would be worth
$356.13
-$643.87 (-64.4%) today · 0.36× · US Dollar
Based on a NXTC entry price of $5.62 vs. today's $2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.88 | $1,063.83 | +6.4% |
| 1 month ago | $2.23 | $896.86 | -10.3% |
| 3 months ago | $11.64 | $171.82 | -82.8% |
| 6 months ago | $13.38 | $149.48 | -85.1% |
| 1 year ago | $5.62 | $356.13 | -64.4% |
| All time (5.0y) ago | $92.4 | $21.65 | -97.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NXTC forecast.
Our base-case forecast reaches $4.00 around 2050.
Implied market cap at $4.00: $14.45M
The multi-year forecast presents a varied trajectory. In 2030 the avg price is $1.69 with a min of $1.05 and a max of $2.94, and a BEARISH sentiment with a -15.3% ROI. Earlier years show interim moves, such as 2031 avg $2.34 (ROI 17.2) and 2033 avg $2.41 (ROI 20.6), reflecting oscillating sentiment.
The outlook strengthens later, with 2040 avg $2.69 (ROI 34.7) and 2050 avg $6.15 (ROI 207.7) and a max of $14.16, supported by a BULLISH sentiment in the distant horizon. These figures imply potential upside into the next decade and beyond, tempered by near-term risk of declines in some years.
Tap a question to reveal the answer.
Avg $1.69, min $1.05, max $2.94; ROI -15.3%; sentiment BEARISH.
Forecast shows mixed signals: neutral in 2026 with avg $2.00, then bearish in 2029-2030, followed by neutral to bullish years from 2031 onward, with a long-term upside to avg $6.15 in 2050 and a max of $14.16.
The max forecast in 2050 is $14.16, so reaching $10 is within the projected range if the upper bound is realized.
Low $1.20, High $3.32.
NextCure, Inc. Community Discussion
0Share your NextCure, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.